ACR Statement on Use of Iodinated Contrast Material for Medical Imaging in Young Children and Need for Thyroid Monitoring.

Abstract

In a March 2022 drug safety communication, the FDA issued guidance recommending that children “through three years old” be monitored for the possibility of hypothyroidism or a temporary decrease in thyroid hormone levels within 3 weeks of exposure to intravascular iodine-containing (iodinated) contrast material (ICM).